Each state has its own rules for which vaccines kids must have to attend school and the reasons students can opt out.
The process will take months, if it's even approved. But just the threat of waiving intellectual property rights could spur faster action.
The survival of the human body is a fine balancing act between cell growth and cell death. Understanding our cells' complex "licence to die" could give us new ways to combat disease.
The US has backed a proposal to waive intellectual property relating to COVID measures – but global efforts need to go beyond vaccine patents.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
It's not clear whether the TRIPS agreement is what's getting in the way of vaccine supply, and waiving intellectual property rights may stifle future innovation.
Plus, a psychologist on how we look back at our big decisions in life. Listen to episode 14 of The Conversation Weekly podcast.
We surveyed social media users from vulnerable groups and found 73% got their vital news from social platforms. How can we protect these people from vaccine misinformation?
It's quite likely this virus will never be eliminated from the world. But even so, getting vaccinated enormously reduces your risk of severe outcomes like hospitalisation and death.
The CDC first paused, then unpaused, the administration of the Johnson & Johnson COVID-19 vaccine due to concerns about blood clots. But what are those clots, and how do they form?
Reports have suggested some women are experiencing changes to their menstrual cycles after having a COVID vaccine.
COVID has now claimed over 200,000 lives on the subcontinent, and the knock-on effects are likely to be substantial.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer's and other mRNA vaccines.
Older adults are assets, but they shouldn’t be commodities.
The COVID-19 vaccination programme requires stringent data collection and transparency.
Licensing agreements between pharmaceutical companies and the Medicines Patent Pool, in cooperation with the WHO, could accelerate access to doses for the poorest countries.
COVID-19 has shown us that we are not "all in this together" despite what politicians may want us to think.
It's normal for different people to mount stronger or weaker immune responses to a vaccine, but post-shot side effects won't tell you which you are.
As more people get vaccinated and different facets of society slowly reopen, challenges remain in the nation's quest to get back to normal. Here are five articles that help illuminate the path.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?